Ultragenyx Pharmaceutical Inc.

RARE12 Jan 2025
Healthcare
$43.01
-0.04 (-3.62%)
Lowest Today
$41.58
Highest Today
$43.72
Today’s Open
$43.01
Prev. Close
$43.65
52 Week High
$60.37
52 Week Low
$37.02
To Invest in Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

Healthcare
RARE12 Jan 2025
-0.04 (-3.62%)
1M
3M
6M
1Y
5Y
Low
$41.58
Day’s Range
High
$43.72
41.58
52 Week Low
$37.02
52-Week Range
52 Week High
$60.37
37.02
1 Day
-
1 Week
-1.36%
1 month return
-10.2%
3 month return
-25.2%
6 month return
-6.88%
1 Year return
-7.98%
3 Years return
-41.05%
5 Years return
-26.98%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
10.77
BlackRock Inc
6.31
Sands Capital Management, LLC
5.54
Wellington Management Company LLP
4.51
T. Rowe Price Associates, Inc.
3.32
Alkeon Capital Management, LLC
3.26
Vanguard Total Stock Mkt Idx Inv
2.98

Market Status

Fundamentals
Market Cap
4030.83 mln
PB Ratio
11.62
PE Ratio
0
Enterprise Value
3443.3 mln
Total Assets
1491.01 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Organisation
Ultragenyx Pharmaceutical Inc.
Employees
1276
Industry
Biotechnology
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step